论文部分内容阅读
选用67例2型糖尿病患者,其中达美康缓释剂组31例,每天30~60mg,1次口服;普通剂型组36例,每天80~160mg2次口服,治疗12周测定空腹血糖(FBG)、餐后2小时血糖(2hPG)、糖化血红蛋白(HbA1c),并观察低血糖事件,进行临床疗效评定。结果:缓释剂组与普通剂型组FBG、2hPG、HbA1c在治疗后均有所下降(P<0.05)。治疗后缓释剂组与普通剂型组FBG、2hPG、HbA1c比较差异无显著性(P>0.05)。低血糖事件两组比较差异无显著性(P>0.05)。结论:达美康缓释剂与普通剂型的疗效和安全性相似。
Sixty-seven patients with type 2 diabetes mellitus were selected, of which 31 cases were treated with metoclopramide and 30-60 mg daily for one time. 36 cases of common dosage form were treated with 80-160 mg twice daily and their fasting blood glucose (FBG) , 2 hours postprandial blood glucose (2hPG), HbA1c, and observed the incidence of hypoglycemia, the clinical efficacy evaluation. Results: FBG, 2hPG and HbA1c in the sustained-release and normal-dosage groups decreased after treatment (P <0.05). There was no significant difference in the FBG, 2hPG and HbA1c between the sustained-release drug group and the ordinary drug-treated group after treatment (P> 0.05). Hypoglycemia events were no significant difference between the two groups (P> 0.05). Conclusion: The efficacy and safety of Deltamethasone sustained-release agent and ordinary dosage form are similar.